20 citations
,
October 2024 in “British Journal of Dermatology” In this updated guideline, the British Association of Dermatologists' expert group provided 49 management recommendations for alopecia areata and highlighted future research priorities, aiming to improve care for individuals affected by this condition.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.
November 2023 in “Dermatology and Therapy” This study found that treatment with baricitinib 4 mg over 52 weeks led to clinically meaningful regrowth of eyebrows and eyelashes in patients with alopecia areata, even without complete scalp hair regrowth.
1 citations
,
October 2023 in “Dermatology and therapy” This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.
June 2023 in “Journal of cosmetic dermatology” This study concluded that both DPCP alone and combined with PRP are effective and safe for treating severe alopecia areata, with no significant difference between the two treatment methods.
4 citations
,
June 2023 in “Frontiers in immunology” This study found that JAK inhibitors effectively improve alopecia areata outcomes, as indicated by SALT scores, but they were associated with an increased risk of adverse effects, with 921 out of 1508 patients experiencing adverse reactions.
3 citations
,
May 2023 in “Clinical drug investigation” This study reviewed the safety of JAK inhibitors for alopecia areata, finding that common side effects included headache and acne, with varying risks for respiratory infections and no increased risk of serious adverse events.
7 citations
,
April 2023 in “Frontiers in immunology” This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
72 citations
,
March 2023 in “Biomolecules” This study reviewed the use of dupilumab, beyond its approved indications for atopic dermatitis and prurigo nodularis, and found effective treatment reports for various chronic inflammatory skin diseases such as bullous autoimmune diseases, eczema, and alopecia areata, highlighting its broad potential in dermatology.
20 citations
,
February 2023 in “American Journal of Clinical Dermatology” In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.
February 2023 in “Lasers in Medical Science” February 2023 in “Journal of Cosmetic Dermatology” This study found that microneedling combined with either topical vitamin D3 or bimatoprost was more effective for hair regrowth in localized alopecia areata than microneedling alone, though differences between the two additives disappeared after three months.
January 2023 in “Journal of cosmetic dermatology” This study concluded that fractional laser therapy, alone or combined with minoxidil or cortisol, effectively treated alopecia areata, showing better outcomes than the drugs alone, without increasing adverse effects, though effectiveness did not significantly differ from similar physical treatments.
29 citations
,
January 2023 in “Journal of Clinical Medicine” This review discusses psychological treatments for alopecia, finding limited but positive effects on mental health, quality of life, and possibly hair growth; however, more research is needed to establish intervention efficacy.
10 citations
,
January 2023 in “Acta dermato-venereologica” In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.
39 citations
,
January 2023 in “Journal of the European Academy of Dermatology and Venereology” This review found that alopecia areata significantly impairs quality of life, particularly through embarrassment and self-consciousness, in children and adolescents.
1 citations
,
December 2022 in “Journal of cosmetic dermatology” This study found that combining a potent steroid with a vitamin D analogue may offer more convenient treatment for localized alopecia areata than using a superpotent steroid alone, with comparable efficacy but fewer side effects.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This review suggests that oral Janus kinase inhibitors are a promising treatment for alopecia areata in adults, showing significant hair regrowth with fewer side effects than conventional treatments, while PDE-4 inhibitors and biologics show limited efficacy.
November 2022 in “Frontiers in Medicine” This review suggests that platelet-rich plasma may be a promising treatment for immune-mediated alopecias, including alopecia areata and primary cicatricial alopecias, but definitive recommendations are limited due to insufficient high-quality evidence.
September 2022 in “Journal of Ayub Medical College Abbottabad” This randomized controlled trial found that intralesional injections of triamcinolone were significantly more effective than platelet rich plasma for treating alopecia areata on the scalp, although platelet rich plasma was considered a viable alternative due to its lack of serious side effects.
3 citations
,
September 2022 in “Archives of dermatological research” In this study, fractional CO2 laser treatment for alopecia areata was found to significantly increase terminal hair and patient satisfaction compared to betamethasone valerate cream alone, highlighting its efficacy and safety both as a standalone and combined treatment.
37 citations
,
August 2022 in “Frontiers in pharmacology” This study found that oral JAK inhibitors are effective and generally well-tolerated for treating alopecia areata, but high recurrence rates after stopping treatment suggest the need for continuous use.
15 citations
,
July 2022 in “Biomedicines” This study found no significant difference in the severity of alopecia areata between treatments with platelet-rich plasma and triamcinolone acetonide; further high-quality trials of PRP are needed.
14 citations
,
June 2022 in “British Journal of Dermatology” This study found that the Alopecia Areata Symptom Impact Scale (AASIS) is a better tool than the Alopecia Areata Quality of Life Index (AA-QLI) for assessing patient-reported outcomes in alopecia areata.
17 citations
,
October 2021 in “Journal of Cosmetic Dermatology” This review found that topical immunotherapy and light/laser therapy may achieve over 50% hair regrowth efficacy in treating extensive alopecia areata in children, with no serious side effects observed.
1 citations
,
January 2021 in “Dermatologic Therapy” This study found that intralesional Candida antigen was as effective as intralesional steroids for treating alopecia areata after 5 months, with significantly lower injection pain reported in the Candida group.
3 citations
,
November 2020 in “Dermatologic Therapy” This study found that intralesional triamcinolone acetonide was more effective than saline for hair regrowth in scalp alopecia areata, with 10 mg/mL showing the best response but more side effects.
4 citations
,
July 2020 in “Journal of Dermatological Treatment” This study found that intralesional minoxidil alone has limited efficacy for non-severe patchy alopecia areata, though it may accelerate hair regrowth compared to spontaneous recovery.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.
10 citations
,
July 2019 in “Indian Journal of Dermatology” This study found that azathioprine pulse therapy and betamethasone both effectively managed alopecia areata with similar hair regrowth results, though betamethasone had significantly more side effects, suggesting azathioprine as a preferable alternative to corticosteroids.
44 citations
,
April 2019 in “Journal of the American Academy of Dermatology” This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.
20 citations
,
March 2019 in “Journal of The European Academy of Dermatology and Venereology” In this study, 5% minoxidil significantly improved outcomes for children and adults with patchy alopecia areata compared to placebo, with moderate quality evidence and no severe adverse events reported, though more research is needed to address remaining uncertainties.
89 citations
,
August 2018 in “JAMA Dermatology” This study found that the level of expected therapeutic regrowth significantly affected hair regrowth outcomes in contact immunotherapy for alopecia areata, suggesting implications for patient education and adherence.
28 citations
,
December 2017 in “Lasers in Medical Science” This review assessed evidence on laser therapies for alopecia areata, reporting that the 308-nm excimer laser showed hair regrowth in several studies, while more research is needed for other laser types.
22 citations
,
May 2017 in “Journal of dermatological treatment” This study found that BD 1/4 dilution was the most effective corticosteroid concentration for intralesional injection to treat localized alopecia areata in adults, with fewer adverse effects than TA.
19 citations
,
October 2015 in “British Journal of Dermatology” This review reports very low quality evidence for the effectiveness and safety of treatments in extensive resistant alopecia areata and emphasizes the need for high-quality randomized controlled trials.
36 citations
,
January 2015 in “Dermatology” In this study, bimatoprost solution showed better results than corticosteroid in terms of rapidity, percentage of hair regrowth, and side effects for treating scalp alopecia areata.
20 citations
,
January 2014 in “Journal of Clinical & Experimental Dermatology Research” This study found that oral zinc sulphate was effective for treating patchy alopecia areata, with a low relapse rate observed after discontinuing treatment.
17 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” The excimer laser may help hair regrow in alopecia areata patients.
49 citations
,
November 2013 in “JAMA dermatology” This study found that topical clobetasol propionate cream was more effective than hydrocortisone cream in reducing hair loss surface area in children with patchy alopecia areata over 24 weeks, with no serious adverse effects.
20 citations
,
January 2013 in “Evidence-based complementary and alternative medicine” This study found that TGPC plus CGT was more effective than CGT alone in reducing alopecia areata severity in children over 12 months, with similar safety profiles.
18 citations
,
August 2012 in “Chinese journal of integrative medicine/Chinese Journal of Integrative Medicine” This study reported that total glucosides of paeony capsules were as effective and safe as compound glycyrrhizin tablets for treating mild to moderate alopecia areata.
20 citations
,
January 2012 in “International journal of trichology” In this study, among various treatments for localized alopecia areata, intralesional and topical steroids were found to be the most effective with no significant side effects.
13 citations
,
July 2011 in “Journal of Dermatological Treatment” This study found that topical pimecrolimus is as effective as clobetasol propionate for treating alopecia areata, with better tolerability in terms of side effects.
48 citations
,
January 2011 in “International journal of trichology” This study found that intralesional triamcinolone acetonide was most effective for hair regrowth in localized alopecia areata, with betamethasone valerate foam also being beneficial, while tacrolimus ointment showed no significant effect.
43 citations
,
November 2009 in “Archives of dermatology” This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.
114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.
27 citations
,
January 2005 in “American Journal of Clinical Dermatology” This pilot study found that azelaic acid treatment for patchy alopecia areata had similar hair regrowth results as anthralin, suggesting it may be an effective topical therapy.
66 citations
,
July 2003 in “International Journal of Dermatology” This study found that betamethasone valerate foam was more effective and well-tolerated than betamethasone dipropionate lotion in treating mild-to-moderate alopecia areata, with higher hair regrowth rates observed.
13 citations
,
August 1995 in “British Journal of Dermatology” This study found that dapsone treatment for severe alopecia areata resulted in hair regrowth rates similar to spontaneous recovery, making it significantly less effective than topical immunotherapy.
